Informazioni
Non ci sono recensioni
Overview of Current Cancer Immunotherapy
Pages 3-17
Punto di Riferimento
per Medici e Operatori Sanitari
per Medici e Operatori Sanitari
LIBRERIA STUDIUM
Immunotherapy of Cancer
An Innovative Treatment Comes of Age
Yamaguchi
Anno
2016
Pagine
358
ISBN
9784431550303
120,00 €
This timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard treatments of surgery, chemotherapy, and radiotherapy. The progress in fundamental understanding of tumor immunology and the recent advances in clinical trials have opened new avenues with a cancer vaccine in 2010 and immunocheckpoint modulation in 2011, with their approval already granted in the United States. Today, there are no doubts, even among experts in cancer chemotherapy and radiotherapy, that the immune system plays a vital role in tumor eradication. Following American approval, many clinical trials of cancer immunotherapy are being conducted.
With this book the reader will readily understand the paradigm shift in cancer treatment and will realize the importance of cancer immunotherapy. The great value of immunotherapy will be obvious, not only for tumor shrinkage but for prolonging patient survival.
-
-
Bacterial Preparations
Pages 21-35
-
Polysaccharides
Pages 37-50
-
BCG
Pages 51-59
-
αβ-T Cells
Pages 63-73
-
NKT Cell-Based Immunotherapy
Pages 75-86
-
Natural Killer Cells
Pages 87-98
-
γδ T Cell-Based Cancer Immunotherapy
Pages 99-119
-
Genetically Engineered T Cells
Pages 121-132
-
Peptide Vaccine
Pages 135-142
-
Personalized Peptide Vaccine
Pages 143-158
-
WT1 Peptide Vaccine for the Treatment of Malignancies: Its Development, Recent Progress, and Future Perspectives
Pages 159-185
-
Protein Vaccine
Pages 187-196
-
Dendritic Cell-Based Vaccine for Cancer
Pages 197-220
-
CpG Motif
Pages 223-233
-
Pattern Recognition by Dendritic Cells and Its Application to Vaccine Adjuvant for Antitumor Immunotherapy
Pages 235-246
-
Novel Adjuvants
Pages 247-260
-
Anti-CTLA-4 Ab
Pages 263-282
-
Anti-PD-1 and Anti-PD-L1 mAbs
Pages 283-294
-
Novel Targets of Immune Inhibitory and Stimulatory Co-signals
Pages 295-305
-
Regulatory T Cells
Pages 309-322
-
MDSC: Myeloid-Derived Suppressor Cells
Pages 323-334
-
Immune-Related Response Criteria and Guidance for Clinical Trials
Pages 337-346
-
Personalized Cancer Immunotherapy: Immune Biomarkers and Combination Immunotherapy
Pages 349-358
